TraceLink grows market position in DACH region by 215%

13 Mar 2018

Customers cite network connectivity, efficiency of partner onboarding, and seamless data exchange as significant differentiators.

TraceLink has announced 215% customer growth in the DACH region (Germany, Austria and Switzerland) for 2017.

TraceLink grows market position in DACH region by 215%

Now serving over 40 customers in the region, TraceLink experienced a 138% growth in revenues from its German, Austrian and Swiss customers in 2017. To meet demand for its expanding DACH customer base, TraceLink has grown its European team by 169%, currently employing 22 native German-speaking team members.

To counter the threat of falsified medicines entering the legal supply chain, companies who manufacture, sell or dispense medications in the European Union must comply with track and trace regulations outlined in the Falsified Medicines Directive (FMD), including serialization, compliance reporting and verification requirements, by February 2019. Characterized by a strong community of small- and mid-sized life sciences organizations, in addition to several domestic large pharmaceutical companies, the DACH region represents a core area in the European market with a significant need for serialization and compliance with the EU FMD.

What DACH Customers and Partners Are Saying

Ortwin Kottwitz, CEO of Germany-based biotech and TraceLink customer, biosyn said: “We have customers and partners located all over the world and could not afford to lose time and resources by establishing individual point-to-point connections. After a thorough evaluation of solution providers, it was clear that TraceLink’s network approach would deliver the scalability we needed while providing a simple and fast connection into the EU Hub.”

Michael Unbehaun, manager engineering projects at R-Pharm Germany, a TraceLink partner, explained: “As a contract manufacturer, we need to be able to connect to multiple customers, managing and sharing data securely and efficiently. By accessing the TraceLink Life Sciences Cloud we can facilitate EU FMD compliance for our customers who supply markets in Europe. The simplicity of the solution, together with our proactive approach, has helped our customers achieve compliance ahead of the regulatory deadline.”

Boris Brunow of Switzerland-based contract packaging organization (CPO) Allpack, a TraceLink customer, said: “Our partnership with TraceLink has allowed us to manage and exchange serialization data more efficiently by eliminating outdated data transfer processes and simplifying the onboarding process for our customers. We evaluated potential partners over a 2-year period, eventually selecting TraceLink for its network approach, as well as its specialist focus in the pharma sector.”

“The EU FMD deadline is now less than a year away, requiring businesses to begin actively preparing for their serialization and regulatory requirements now. Over 190 companies are already serializing with TraceLink and with more than 265,000 partners on our network, we are well positioned to serve the growing number of companies of all sizes in Germany, Austria and Switzerland,” said Shabbir Dahod, president and CEO, TraceLink. “On an organizational level, we now have more employees dedicated to serving the DACH region than some of our competitors have for total number of employees, giving TraceLink a distinct advantage in our ability to service the specific needs of pharmaceutical and contract manufacturers across the region.”

To support companies’ compliance and serialization challenges in both the DACH region and across Europe, TraceLink is hosting FutureLink in Munich from 5–7 June 2018. FutureLink is the industry’s largest annual gathering of commercial and operational executives from the pharmaceutical and healthcare industries. The conference provides distinct learning forums for a range of business leaders to develop strategies that address rapidly approaching compliance deadlines — and to discuss the analog-to-digital information-sharing transformation taking place in the pharmaceutical and healthcare industries.

Read More

Related news

Moulds & Tooling: A European success story

Moulds & Tooling: A European success story

19 Sep 2018

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Exciting skincare to protect against blue light emitted by phones and devices

Exciting skincare to protect against blue light emitted by phones and devices

10 Sep 2018

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Read more 
Bio processing and manufacturing league table ranks US top and China bottom

Bio processing and manufacturing league table ranks US top and China bottom

3 Sep 2018

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Read more 
Innovation hindered by regulators

Innovation "hindered by regulators"

27 Aug 2018

CPhI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.

Read more 
The 6-month FMD countdown - are you ready?

The 6-month FMD countdown - are you ready?

21 Aug 2018

With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?

Read more 
Protecting the links between the UK and the EMA

Protecting the links between the UK and the EMA

14 Aug 2018

Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Post-Brexit medicines - stuck in the UK?

Post-Brexit medicines - stuck in the UK?

30 Jul 2018

The EMA needs to provide more action and guidance to help UK pharmaceutical manufacturers, says Thomas Beck, senior vice president, quality management, Recipharm.

Read more 
Pharmacovigilance post-Brexit - simpler than previously thought?

Pharmacovigilance post-Brexit - simpler than previously thought?

24 Jul 2018

To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".

Read more